HemoShear Therapeutics is a clinical-stage company that develops treatments for rare metabolic disorders using its REVEAL-Tx platform to create biologically relevant human disease models. Its lead program is HST5040, an investigational oral small molecule for methylmalonic acidemia (MMA) and propionic acidemia (PA) that has received FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations. The company plans to complete its HERO phase 2 study of HST5040, which will enroll at least 12 patients aged 2 and older at select U.S. children’s hospitals. HemoShear also pursues earlier-stage proprietary rare disease programs and holds exclusive partnerships with Takeda on NASH and an undisclosed rare liver disease, and with Horizon Therapeutics on gout. The company intends to use the $40M Series A to finish the phase 2 study and to fund future clinical studies and earlier-stage programs. HemoShear is led by Chairman and CEO Jim Powers and is based in Charlottesville, Va. HemoShear develops and applies human disease systems, integrating proprietary technology, scientific expertise and predictive analytics to uncover targets, resolve mechanisms, identify drug attributes and select candidates with improved efficacy and safety. Led by CEO Jim Powers, the company focuses on building biological systems for tumors and rare diseases. It intends to use new funding to relocate operations to facilities in Charlottesville, support future expansion, accelerate development of its human disease systems and recruit scientific and bioinformatics expertise. Founded in 2008, HemoShear has partnered with major pharmaceutical and biotechnology companies to expand its scientific platform and business. The company has received public funding in addition to private investment to support its work. HemoShear creates human- and animal-cell surrogate systems that replicate the biology of organ systems and diseases to support drug discovery and development. Its platforms are used by pharmaceutical, biotechnology and medical device companies for discovery and assessment of new drug compounds. The company plans to use recent funding to move to larger lab and office facilities next year, invest in scientific and business staff, and provide working capital to accelerate growth. HemoShear closed a fourth equity financing of $4M to support these initiatives; backers were not disclosed. Founded in 2008, the company currently has thirty employees. The business is led by CEO Jim Powers and CFO Brian Campbell.

Total raised

$53M

Funding rounds

3

Latest round

Series A

Latest activity

Feb 2021